Pharmaceutical composition of dsRNA and saikosaponin and application thereof

A saikosaponin and drug technology, applied to the drug combination of dsRNA and saikosaponin and its application field, can solve the problem of low fever, no compatibility of active substances, lack of suitable conditions for double-stranded pairing, systematic research on factors affecting stability, etc. question

Inactive Publication Date: 2010-05-12
青岛汉河动植物药业有限公司
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, although there are domestic production of oligoinosinic acid and oligocytidylic acid raw materials, there is still a lack of systematic research on the suitable conditions for double-strand pairing and factors affecting stability, and there is no compatibility

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition of dsRNA and saikosaponin and application thereof
  • Pharmaceutical composition of dsRNA and saikosaponin and application thereof
  • Pharmaceutical composition of dsRNA and saikosaponin and application thereof

Examples

Experimental program
Comparison scheme
Effect test

specific Embodiment approach 1

[0017] Embodiment 1: This embodiment adopts the following technical scheme: its formula consists of: polykinocytes, saikosaponin and Bupleurum volatile oil; its preparation method is: adding appropriate pharmaceutical excipients to the above components by a certain amount The process is made into a compound preparation; these components have certain synergistic and synergistic effects, and can avoid the side effects of dsRNA.

specific Embodiment approach 2

[0018] Specific implementation mode two: refer to figure 1 , The specific embodiment adopts the following technical scheme: take two groups of test rabbits, inject the simple polyinocide injection and the combined medicine respectively to carry out the pyrogen test, and record the temperature changes of the test rabbits. The results showed that the combined drug could alleviate the pyrogen reaction of poly-inosin injection alone.

specific Embodiment approach 3

[0019] Specific implementation mode three: refer to figure 2 and image 3 , the specific embodiment adopts the following technical scheme: the drug combination is diluted to 50 μg / ml with water for injection. 240 test chicks are randomly divided into 6 test groups, each group of 40. I group: blank control group; II Group: drug control group (astragalus polysaccharide injection, 20 mg per kg body weight); III group: vaccine control group (no drug); IV group: high-dose drug combination test group (0.1 mg per kg body weight); V group: medium Dosage drug combination test group (0.05mg per kilogram body weight); VI group: low dose drug combination test group (0.01mg per kilogram body weight). The chicken coops were raised, and the feeding conditions were kept the same. After 10 days of feeding, four groups III, IV, V, and VI were immunized with Newcastle disease vaccine. Each group was divided into two groups, and some of them were immunized with II, IV vaccine 15 days after immu...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a pharmaceutical composition of dsRNA and saikosaponin and application thereof, in particular to the pharmaceutical composition applied to viral infection prevention and treatment of cultured animals, a preparation method and stability control method thereof. The pharmaceutical composition comprises the following ingredients: 20-50mu g/ml of saikosaponin, bupleurum oil with the content range of ultraviolet absorption value of above 0.45; and 1-3mg/ml of polyinosinic polycytidylic acid with the molecular weight range of 200-500bp (agarose gel electrophoresis method). The preparation method of the pharmaceutical composition comprises the steps of adding proper pharmaceutic adjuvant into the ingredients, matching liquid, filtering, filling and encapsulating, and sterilizing according to water injection production technology, and obtaining the pharmaceutical composition after being checked to be qualified. The pharmaceutical composition can induce animal organism to generate endogenous interferon, thus avoiding virus breeding in the animal bodies.

Description

Technical field: [0001] The invention relates to a drug combination applied to the prevention and treatment of viral infection in farmed animals and a method for preparing and stabilizing the drug used in the combination, in particular to a drug combination of dsRNA and saikosaponin and its application. Background technique: [0002] Viral infection is an important factor that causes the death of farmed animals and affects the economic benefits of animal breeding. With the standardization of national veterinary drug quality standards, a large number of antiviral drugs with original local standards have been cancelled. Demand contradictions are becoming increasingly prominent. [0003] In 1967, Field et al. of Merck Pharmaceutical Company in the United States discovered that enzymatically synthesized double-stranded nucleic acid (double strained RNA, dsRNA) has the ability to induce interferon, wherein the induction of polyinosinic-polycytidylic acid (PIC) It has the stronge...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K36/233A61P31/12A61K31/713A61K31/7048A61K31/704A61K125/00
Inventor 刘宗柱尹立杰段坤刘西锋
Owner 青岛汉河动植物药业有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap